{"prompt": "['2016N298481_02', 'CONFIDENTIAL', '205270', '7.9.', 'Treatment after the End of the Study', 'Participants will not receive any additional treatment from GSK after completion of the', 'study. The investigator is responsible for ensuring that consideration has been given to', \"post-study care of the participant's medical condition.\", '8.', 'DISCONTINUATION CRITERIA', '8.1.', 'Discontinuation of Study Treatment', 'Every effort should be made to keep participants in the study including those who', 'permanently stop randomized treatment. A participant may permanently discontinue', 'randomized treatment at any time at his/her own request, or at the discretion of the', 'investigator for safety, or compliance reasons. However, treatment should not be', 'discontinued due to an inadequate hemoglobin response to the study treatment, by the', 'investigator, since in such instances the study treatment dosing algorithm (Table 6) or the', 'rescue criteria (Section 7.7.2) should be followed.', 'A participant must permanently discontinue study treatment for the following reasons,', 'and should continue attending study visits as outlined in the SoA for participants that', 'discontinued study treatment (Section 12.2 Appendix 2):', 'Participant receives a kidney transplant', 'Participant initiates dialysis', 'Participant meets the criteria to receive rescue therapy (Section 7.7.2).', 'Participant becomes pregnant or intends to become pregnant during the study.', 'Liver chemistry abnormalities exceed the threshold criteria (Section 8.1.1).', 'Diagnosis of cancer (new or recurrent), with the exception of localized', 'squamous cell or basal cell carcinoma of the skin.', 'Need for more than 14 days of prohibited medication (Section 7.8.2).', 'ADPKD participants only: following further imaging, condition of the cystic', 'disease in the kidney(s) has worsened more than expected given the clinical', 'scenario and no other cause for the kidney function decline and/or cyst', 'enlargement can be identified (Section 9.5.4).', 'In all cases, the reason for study treatment discontinuation and the date of the last dose', \"will be recorded in the participant's eCRF.\", '8.1.1.', 'Liver Chemistry Stopping Criteria', 'Liver chemistry stopping and increased monitoring criteria have been designed to', 'assure participant safety and evaluate liver event etiology.', 'Discontinuation of study treatment for abnormal liver tests is required when:', 'A participant meets one of the conditions outlined in the algorithm', '50']['2016N298481_02', 'CONFIDENTIAL', '205270', 'In the presence of abnormal liver chemistries not meeting protocol-specified', 'stopping rules, the investigator believes study treatment discontinuation is in the', 'best interest of the participant.', 'Algorithm A: Phase III-IV Liver Chemistry Stopping and Increased Monitoring', 'Algorithm', 'Continue Study Treatment', 'Plus', 'No', 'Bilirubin>2x', 'Plus', 'See algorithm', 'ULN(>35%', 'Yes', 'No', 'Symptoms of', 'ALT', 'direct)orplus', 'No', 'ALT', 'No', 'Yes', 'for continued', 'ALT>3xULN)', 'liverinjury', '>3xULN', 'therapy with', 'INR>1.5, if', '>8xULN', 'or', 'but', 'increasedliver', 'measured*', 'hypersensitivity', '<8xULN', 'chemistry', 'Possible', 'monitoring', \"Hy's Law\", 'Yes', 'Yes', 'Yes', 'Discontinue Study Treatment', 'Must refer to Liver Safety Required Actions and Followup Assessments section in the Appendix', \"Reportas an SAE if possible Hy's Lawcase:ALT=3xULNand Bilirubin>2xULN(>35% direct) or\", 'INR>1.5, if measured*', '\"INR value notapplicable: to subjectsonanticosgulants', 'Liver Safety Required Actions and Follow up Assessments Section can be found in', 'Section 12.6 (Appendix 6).', '51']\n\n###\n\n", "completion": "END"}